Interactions of Everolimus and Sorafenib in Pancreatic Cancer Cells

Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 1

Abstract

Everolimus targets the mammalian target of rapamycin, a kinase that promotes cell growth and proliferation in pancreatic cancer. Sorafenib inhibits the Raf-mitogen-activated protein kinase, vascular endothelial growth factor, and platelet-derived growth factor pathways, thus inhibiting cell growth and angiogenesis. Combinations of these two agents are under evaluation for therapy of several cancers. This study examined the effects of everolimus and sorafenib on proliferation of the pancreatic cancer cell lines MiaPaCa-2 and Panc-1. Cell growth inhibition was evaluated in vitro for a range of concentrations of the drugs alone and in combination. Maximum inhibition capacity (Imax) and potency (IC50) were determined. The data were analyzed to characterize drug interactions using two mathematical analysis techniques. The Ariens noncompetitive interaction model and Earp model were modified to accommodate alterations in the inhibition parameters of one drug in the presence of another. Sorafenib alone inhibited growth of both cell lines completely (Imax = 1), with an IC50 of 5–8 μM. Maximal inhibition by everolimus alone was only 40% (Imax = 0.4) in both cell lines, with an IC50 of 5 nM. Slight antagonistic interaction occurred between the drugs; both analytic methods estimated the interaction term Ψ as greater than 1 for both cell lines. The in vitro data for two pancreatic cancer cell lines suggest that a combination of these two drugs would be no more efficacious than the individual drugs alone, consistent with the drug interaction analysis that indicated slight antagonism for growth inhibition.

Authors and Affiliations

Dipti K. Pawaskar, Robert M. Straubinger, Gerald J. Fetterly, Wen W. Ma, William J. Jusko

Keywords

Related Articles

The effect of alkylpolyglycoside surfactants on the crystallization of spray-dried salbutamol sulphate: a gravimetric near-infrared spectroscopy study

This study monitored the effect of a series of structurally related surfactants on the crystallization of amorphous salbutamol sulphate. Amorphous salbutamol sulphate was prepared by spray drying from a solution in water...

Choice of LC-MS Methods for the Absolute Quantification of Drug-Metabolizing Enzymes and Transporters in Human Tissue: a Comparative Cost Analysis

The online version of this article (doi:10.1208/s12248-014-9712-6) contains supplementary material, which is available to authorized users.

Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice

Drug treatment poses a therapeutic challenge in cystic fibrosis (CF) because the disposition of a number of drugs is altered in CF. Enhanced clearance of acetaminophen (APAP) and indocyanine green (ICG) have previously b...

Regulator of G-protein Signaling (RGS)1 and RGS10 Proteins as Potential Drug Targets for Neuroinflammatory and Neurodegenerative Diseases

Regulator of G-protein signaling (RGS) proteins were originally identified as negative regulators of G-protein-coupled receptor (GPCR) signaling via their GTPase-accelerating protein (GAP) activity. All RGS proteins cont...

Viewing chemokines as a third major system of communication in the brain

There is irrefutable proof that opioids and other classes of centrally acting drugs have profound effects on the immune system. Evidence is mounting that products of the immune system, such as chemokines, can reciprocall...

Download PDF file
  • EP ID EP681749
  • DOI  10.1208/s12248-012-9417-7
  • Views 72
  • Downloads 0

How To Cite

Dipti K. Pawaskar, Robert M. Straubinger, Gerald J. Fetterly, Wen W. Ma, William J. Jusko (2013). Interactions of Everolimus and Sorafenib in Pancreatic Cancer Cells. The AAPS Journal, 15(1), -. https://europub.co.uk/articles/-A-681749